<DOC>
	<DOCNO>NCT02942290</DOCNO>
	<brief_summary>This randomize , Phase 2 , dose-ranging study evaluate safety , pharmacokinetics ( PK ) , efficacy venetoclax administer combination azacitidine participant treatment-naïve higher-risk ( HR ) MDS compare azacitidine monotherapy .</brief_summary>
	<brief_title>A Study Evaluating Venetoclax Combination With Azacitidine Compared With Azacitidine Alone Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Participant must document diagnosis de novo MDS : International Prognostic Scoring System ( IPSS ) risk category Int2 High ( IPSS overall score ≥ 1.5 ) Presence great equal 5 % le 30 % bone marrow blast per bone marrow Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Participant receive prior therapy MDS . NOTE : Participants receive supportive care MDS ( e.g. , transfusion , growth factor ) eligible enrol study . Participant candidate undergo intensive chemotherapy allogeneic hematopoietic stem cell transplantation ( HSCT ) . Participant therapyrelated MDS ( tMDS ) . Participant MDS evolve preexist myeloproliferative neoplasm ( MPN ) Participant MDS/MPN include chronic myelomonocytic leukemia ( CMML ) , atypical chronic myelogenous leukemia ( CML ) , juvenile myelomonocytic leukemia ( JMML ) unclassifiable MDS/MPN . Participant receive prior therapy BH3 mimetic . Participant receive allogeneic HSCT solid organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Higher-Risk ( HR ) Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>Venetoclax</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>